HOME > BUSINESS > Cadila to launch immunosuppressant drug in India

Cadila to launch immunosuppressant drug in India

zydusCadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body’s immune system in India.

The drug named Grafalon is extensively used in solid organ transplants and stem cell transplant, said the company.

The market for transplant-immuno therapies is estimated at Rs 483 crore, the company added.

Zydus will market this therapy through Zydus Trans-immune a division that offers a range of therapies related to transplant medicine.

With the inclusion of Grafalon (R) Zydus Trans-immune becomes a leading player in transplant-immunotherapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant.

Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation, the company further added.

One of the major challenges in organ transplantation is graft rejection.

In most cases transplant rejection occurs when transplanted tissue is rejected by the recipient’s immune system which destroys the transplanted tissue.

Likewise, stem cell transplantation remains key treatment option for those suffering from haematological conditions including malignancies.

Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon (R).

Grafalon(R) enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world.

More than 200,000 patients till date, in over 50 countries, have been treated With Grafalon (R) currently an estimated 10000 Solid organ transplant & stem cell transplants are taking place annually across 200 plus transplant centres in India.

Follow ULTRA.news
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
Zydus Cadila gets approval for cholesterol drug in Mexico Zydus Cadila said Mexico's drug regulator granted marketing approval to market its diabetes drug Lipaglyn in Mexico.The drug can be used to bring down cholesterol levels in patients even when conventional therapies like statins fail.“This approval of Saroglitazar in Mexi...
Royal Orchid Hotels inks marketing tie-up with UK’s Bespoke Hotels Royal Orchid Hotels said it had tied up with Bespoke Hotels of the UK to market each others' properties to their customers.Bespoke manages over 200 hots with 9,500 hotel rooms, 8,000 employees and £815 million of assets."Royal Orchid now has the ability to offer its gues...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
Zydus Cadila gets USFDA nod for overactive bladder drug Zydus Cadila said it received the final approval to launch overactive bladder drug Fesoterodine Fumarate in the US.The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at $195.5 million.It will be manufactured at the group’s formulations manufacturin...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system.The drug, Glat...
Cyient ties up with US start-up to incorporate AI tech in power solution Mumbai-based IT services provider Cyient said it has signed an agreement to incorporate machine learning meter and voltage signature technology from US-based startup Elpis in its solutions for power utilities."Through this agreement, Cyient and Elpis will jointly pursue util...
Infosys to deliver private cloud solution based on Suse Linux and Openstack IT services provider Infosys said it now offers a private cloud solution built using SUSE Linux and Openstack.The solution will make use of Openstack cloud and datacenter solutions developed by Germany-based Micro Focus SUSE.Infosys and Micro Focus SUSE have jointly inve...
Vivimed pharma unit gets Rs 270 cr investment from OrbiMed fund Pharmaceuticals and specialty chemicals maker Vivimed Labs said investment firm OrbiMed will invest $42.5 mn (Rs 270 cr) into its active pharmaceutical ingredients business.The investment will be into Vivimed Labs Mascarene Ltd, which is in turn the holding entity of the com...
L&T Technology Services to co-develop solutions with Intel unit L&T Technology Services, the engineering services arm of the construction conglomerate, will co-develop industrial solutions with Intel subsidiary Wind River, which works in the emerging domain of Internet of Things.Under the partnership L&T Technology Services will "validat...
Glenmark to launch Desonide topical ointment in US Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo's anti-inflammation ointment Desonide Ointment in the US.Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, acco...
Biocon passes US-FDA inspection at Vishakapatanam plant Biocon said the plant inspection conducted by the US Food and Drug Administration at its Vishakapatanam plant passed without incident."US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Wishakhapatnam, Andhra Pradesh from September 11 to 1...